Tag Archives: UK
By Guest Blogger | Published: September 21, 2012
By Martin Smith and Tim Suter. A recent decision by the Department of Health (DoH) to introduce a compliance regime for NICE (National Institute for Health and Clinical Excellence) technology appraisals will open the door to ensuring better implementation by NHS Trusts and Joint Prescribing Groups of NICE guidance. Importantly, the regime will also open new avenues [...]
By Ben Comer | Published: July 18, 2012
Like governors in the US vowing to block Medicaid expansion in their home states, local primary care trusts (PCTs) in the UK don’t always follow national guidelines on drug access due to budgetary concerns. But that may change in 2013; according to comments made by Minister David Willetts last month, NHS could face monetary penalties [...]
By Julian Upton | Published: March 21, 2012
UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times.
By Julian Upton | Published: December 5, 2011
Patient Privacy Fears Taint UK Innovation Plans The Conservative arm of the UK’s coalition government flexed its private-sector-friendly muscles again on Monday with the announcement that the National Health Service should be ‘opened up’ to private healthcare firms. In a pharma-friendly speech peppered with the usual buzzwords, Prime Minister David Cameron said: “The end-game is for [...]
By Julian Upton | Published: March 25, 2011
The UK government’s proposals to introduce value-based pricing (VBP) — which aims to create a stronger link between the price the National Health Service pays for a medicine and the value it delivers (and in the process, ostensibly, further incentivize therapeutic innovation) — could actually serve to ‘hinder’ innovation, according to a UK think tank.